

## **Centre For AIDS Reagents**

<u>Data Sheet</u>
-------------------

DESCRIPTION:	J-Lat GFP Cells (A72)
<b>REPOSITORY REFERENCE:</b>	100 948
<b>RELEASE CATERGORY:</b>	NIH Restriction C
LOT NUMBER:	120236
PROVIDED:	1 ml (4.5 x 106 cells/vial), viability is 88%
STORAGE:	Liquid nitrogen
DESCRIPTION:	These Jurkat cells contain a single integration site of a HIV retroviral vector expressing LTR driven GFP expression.
SPECIAL CHARACTERISTICS:	Jurkat cells were infected with viral particles bearing the retroviral construct LTR-Tat-IRES-GFP. Cells that were GFP negative, but could be stimulated to express GFP were selected. For the other similar cells, please see cat#s 100941- 100948.
CELL TYPE:	Jurkat - T lymphocyte cell line
FREEZE MEDIUM:	FBS, 90%; DMSO, 10%.
GROWTH CHARACTERISTIC:	No special requirements, split 1:3 at $1 \times 106$ /ml. Cells grow in suspension, usually singly but some clumping has been noted.
PROPAGATION MEDIUM:	RPMI 1640, 90%; FBS, 10%; supplemented with penicillin G (100U/ml), streptomycin (100 µg/ml), L-glutamine (2 mM, 0.3 mg/ml).
MORPHOLOGY:	Small, spherical cells in suspension. Morphology usually does not vary.
CONTRIBUTOR:	Dr. Eric Verdin.
<b>REFERENCES:</b>	Jordan A, Bisgrove D, Verdin E. HIV reproducibly establishes a latent infection after acute infection of T cells in vitro. <i>EMBO J</i> <b>22</b> :1868-1877, 2003.
	Jordan A, Defechereux P, Verdin E. The site of HIV-1 integration in the human genome determines basal transcriptional activity and response to Tat transactivation. <i>EMBO J</i> 20:1726- 1738, 2001.



## **ACKNOWLEDGMENT:**

The following reagent was obtained by CFAR – NIBSC via the NIH AIDS Reagent Program, Division of AIDS, NIAID, NIH: J-Lat GFP Cells (clone #) from Dr. Eric Verdin. Also include the references cited above in any publication.
Please ensure that you send us a copy of any papers Resulting from work using reagents acquired through CFAR, this can be by e-mail or printed copy.